$CTIX Recent Headlines Cellceutix Brilacidin IND

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
$CTIX Recent Headlines

Cellceutix Brilacidin IND effective, Phase 2 to begin 9:31 a.m. Oct. 13, 2014 - Seeking Alpha
Regulatory Support Creates Opportunity For Antibiotic Makers Otonomy And Cellceutix 9:02 a.m. Sept. 25, 2014 - Seeking Alpha
Update: Cellceutix Calls Out To President Obama About Brilacidin 2:38 p.m. Sept. 21, 2014 - Seeking Alpha
10-K: CELLCEUTIX CORP 12:53 p.m. Sept. 15, 2014 - Edgar Online - (EDG = 10Q, 10K)
Update: Cellceutix's Antibiotic Brilacidin Should Move Share Price Before Kevetrin Or Prurisol 2:06 a.m. Sept. 14, 2014 - Seeking Alpha
The Antibiotic Resistance Triple Threat 1:05 p.m. Sept. 4, 2014 - Seeking Alpha
Cellceutix completes enrollment in Brilacidin trial 8:45 a.m. Aug. 19, 2014 - Seeking Alpha
Did The Medicines Company Trump Cellceutix And Others In A $1B-Plus Skin Infection Market? 10:38 a.m. Aug. 14, 2014 - Seeking Alpha
10-Q: CELLCEUTIX CORP 9:15 a.m. May 12, 2014 - Edgar Online - (EDG = 10Q, 10K)
Huge Opportunities Are Now Possible Due To Market Inefficiencies In Valuing Antibiotic Companies Such As Cubist, Durata, And Cellceutix 9:34 a.m. April 25, 2014 - Seeking Alpha
10-Q: CELLCEUTIX CORP 4:09 p.m. Feb. 10, 2014 - Edgar Online - (EDG = 10Q, 10K)
Cellceutix Is Significantly Undervalued Considering The Value Of Brilacidin 9:31 a.m. Jan. 28, 2014 - Seeking Alpha
Cellceutix Corp.: A Biotech With High Risk But High Reward 3:17 p.m. Jan. 2, 2014 - Wall St. Cheat Sheet
Cellceutix: An Undiscovered Company Set To Rise In 2014 9:06 a.m. Dec. 16, 2013 - Seeking Alpha
3 Innovative Biotech Companies Poised To Shine At TAP Partnership Conference 5:38 a.m. Nov. 19, 2013 - Seeking Alpha
10-Q: CELLCEUTIX CORP 5:06 p.m. Nov. 8, 2013 - Edgar Online - (EDG = 10Q, 10K)
10-K: CELLCEUTIX CORP 3:01 p.m. Sept. 30, 2013 - Edgar Online - (EDG = 10Q, 10K)
10-Q: CELLCEUTIX CORP 1:18 p.m. May 20, 2013 - Edgar Online - (EDG = 10Q, 10K)
Interview with CEO of Cellceutix Corporation: Leo Ehrlich 8:57 a.m. Nov. 15, 2011 - GuruFocus.com

Patient Enrollment in Cellceutix Phase 2 Clinical Trial of Brilacidin-OM for Oral Mucositis Targeted to Begin in December 2014 7:01 a.m. Today - Marketwired
Cellceutix's New Chief Operating Officer Dr. James Alexander Addresses Shareholders 6:00 a.m. Oct. 31, 2014 - Marketwired
Cellceutix Announces Positive Top-Line Data From Phase 2b ABSSSI Trial; Single-Dose Brilacidin Comparable to 7-Days of Daptomycin 10:52 a.m. Oct. 23, 2014 - Marketwired
Cellceutix Investigational New Drug (IND) Application Becomes Effective, Selects First Site for Phase 2 Clinical Trial of New Treatment for Oral Mucositis 8:02 a.m. Oct. 13, 2014 - Marketwired
Cellceutix Provides Update to Shareholders 11:30 a.m. Sept. 24, 2014 - Marketwire
Cellceutix to President Obama: We Have the Tools and Will Rise Up to the Challenge to Prevent Antibiotic Resistant Bacteria Becoming a Serious Threat to Public Health 6:15 a.m. Sept. 19, 2014 - Marketwire
Cellceutix Provides Initial Observations of Completed ABSSSI Phase 2b Trial; Company Submits Investigational New Drug Application to FDA for Phase 2 Trial of Brilacidin-OM for Oral Mucositis 2:01 p.m. Sept. 9, 2014 - Marketwire
Cellceutix to Present at Rodman & Renshaw's 16th Annual Global Investment Conference 10:17 a.m. Sept. 5, 2014 - Marketwire
Cellceutix Appoints Dr. Barry Schechter to Board of Directors as Company Focuses on Meeting Requirements for Stock Exchange Uplisting 6:01 a.m. Sept. 2, 2014 - Marketwire
Cellceutix Completes Enrollment in Phase 2b Clinical Trial of Brilacidin for Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 7:31 a.m. Aug. 19, 2014 - Marketwire
Cellceutix Prepares for Phase 2 Clinical Trial of Brilacidin-OM for Oral Mucositis 6:01 a.m. Aug. 11, 2014 - Marketwire
Cellceutix Anti-Psoriasis Drug Prurisol Meets Primary Endpoint of Clinical Trial 5:04 a.m. Aug. 8, 2014 - Marketwire
Cellceutix Believes Brilacidin on Track to Help U.S. Avoid Falling Into Post-Antibiotic Era; Completion of Enrollment in Phase 2b Trial for Acute Bacterial Skin and Skin Structure Infections Expected This Month 6:01 a.m. Aug. 4, 2014 - Marketwire
Cellceutix Announces Breakthrough in the Formulation of Its Novel Antibiotic Brilacidin(TM), Plans Studies to Treat Diabetic Foot Ulcers 6:01 a.m. July 14, 2014 - Marketwire
Cellceutix Brilacidin ABSSSI Trial Gets Positive Review by Data Safety Monitoring Board; Best Possible Outcome, No Treatment-Related Serious Adverse Events (SAEs) 6:00 a.m. July 7, 2014 - Marketwire
Cellceutix Anti-Fungal Compounds Awarded $1.5 Million SBIR Grant 6:01 a.m. June 23, 2014 - Marketwire
Cellceutix Clinical Trial of Anti-Cancer Drug Kevetrin Entering Eighth Cohort 6:01 a.m. June 16, 2014 - Marketwire
Cellceutix Completes Patient Enrollment in Clinical Trial of Prurisol 6:02 a.m. June 2, 2014 - Marketwire
Cellceutix Signs Material Transfer Agreements for Defensin Mimetic Compounds With Leading Universities 6:02 a.m. May 27, 2014 - Marketwire
Cellceutix Plans for Entry in Diabetic Foot Wound and Ulcer Market 6:01 a.m. May 19, 2014 - Marketwire

Scroll down for more posts ▼

Top 10 Most Recent News Articles

BMO's Strategic Exit: Transportation Finance Sale

Updated Category News Views 34

A Major Shift in BMO’s Strategic Direction When it comes to banking, BMO ain't playing small ball. They've just doubled down on their decision to part ways with their Transportation Finance and Vendor Finance operations, selling off a hefty part of these portfolios to Stonepeak. Now, that might sound like a mouthful, but hang tight, the nitty-gritty's where it gets...

Continue Reading
IANS Enhances Cybersecurity with Microsoft Copilot Integration

Updated Category News Views 43

Cybersecurity Intelligence Meets Convenience Imagine the chaos of a Monday morning without your go-to coffee: that's your security team trying to make informed decisions without robust data. But now, with a dash of innovation, IANS has amped up the stakes by integrating its wealth of cybersecurity intelligence with Microsoft Copilot. It's no small beans, folks. The...

Continue Reading
ZYNLONTA's Japanese Push: ADC Therapeutics Gains Traction

Updated Category News Views 51

ADC Therapeutics Eyes Japan with ZYNLONTA Bet These days, everyone seems to have their eyes on the Far East, and ADC Therapeutics is no exception. They're making a strategic leap by letting their budding blockbuster ZYNLONTA make waves in Japan. With the fresh file submitted for approval, it looks like they're hoping to capture market ground that could pay off big time...

Continue Reading
Abel Leads PRSA Maryland Chesapeake as New Chapter President

Updated Category News Views 17

New Leadership and Opportunities in the PR Landscape Amid all the hustle and bustle of the corporate world, something big's brewing in Baltimore's public relations sphere. Greg Abel, the go-getting mastermind behind Abel Communications, has taken the helm of the newly formed PRSA Maryland Chesapeake chapter. This isn't just about shifting chairs or fancy titles—this...

Continue Reading
Webull Faces Class Action: Investor Impact Deep Dive

Updated Category News Views 99

What's Going On with Webull? Ah, Webull Corporation, you're in the hot seat now. If you blinked on October 7th, you might have missed a monumental 19.09% cliff dive in Webull's stock, tumbling down to a humble $5.89. The roar wasn't just the market reacting; it was the sonic boom of a class action lawsuit on their heels, alleging some slick legal sledding with misleading...

Continue Reading
Victory Gala Honors Heroes, Raises Over $500K

Updated Category News Views 50

A Night Celebrating Service and Sacrifice You know, in times like these, it’s refreshing to see events that focus on giving back rather than taking everything to the bank. Victory Home Remodeling, along with its nonprofit arm, the Victory Foundation, recently hosted their second annual gala in Woodland Park, New Jersey to give some much-needed limelight to those who put...

Continue Reading
SKE Invigorates IRONWORKS London's Music Vibe With E-Cigs

Updated Category News Views 57

Bringing SKE's Flair to London's Music Scene Well, folks, hold onto your hats—SKE's thrown its weight behind IRONWORKS London, extending its reach deeper into the UK's electronic music scene. This ain't just another gig; we're talking about the second time SKE is flexing its sponsorship muscles in the UK music arena, officially angling for the vape category spotlight....

Continue Reading
TIOmarkets App Unveils Enhanced Trading Features

Updated Category News Views 94

Trading on the Go Takes a Leap Forward Pretty slick development from TIOmarkets, if I do say so myself. They've rolled out a major expansion of their mobile trading app, now packing some hefty features like Depth of Market and more granular order controls right from those little devices in our pockets. Quite the leap if you're one of those folks who can't keep your eyes...

Continue Reading
Rockford Fosgate Elevates Marketing Maverick to Lead Role

Updated Category News Views 40

Changing the Guard in High-Performance Audio Marketing Out of Arizona, we get a shake-up that feels like a no-brainer for anyone in the high-performance audio market. Rockford Fosgate decided to elevate Tammy Lowe to the Vice President of Marketing role, effective immediately. With nearly four decades under her belt at the sunny Tempe-based HQ, it's hard to argue with the...

Continue Reading
Concurrence Expands Reach With Microsoft Marketplace

Updated Category News Views 50

Concurrence's Big Move into Microsoft's Court From the bustling streets of New York to the mighty tech avenues of Seattle, Concurrence is making waves that could leave a whale-sized impact on the healthcare sector. As of today, their Health World Model and snazzy AI agents have entered the Microsoft Marketplace, marking a significant leap forward. For the uninitiated,...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring the Growth of Generative AI: Key Insights Unveiled

Updated Category News Views 102

Understanding Generative AI Adoption Trends Generative AI is rapidly gaining traction across various sectors, with many organizations exploring its potential benefits. Through an extensive analysis of recent statistics, we gain valuable insights into how generative AI is being embraced and utilized within business landscapes. Key Developments in Generative AI The analysis...

Continue Reading
Expanded Overview of Riksbank Certificates for Sale

Updated Category News Views 159

Understanding Riksbank Certificates The Riksbank, Sweden's central bank, periodically issues certificates that serve as financial instruments designed to manage liquidity within the economy. These certificates reflect the banking system’s demand for funds while ensuring the stability of monetary policy. Let’s explore the detailed conditions surrounding the sale of...

Continue Reading
Transforming Automotive Experience: Touch Screen Control Systems

Updated Category News Views 214

Growth in Automotive Touch Screen Control Systems Market The automotive touch screen control systems market is on the verge of impressive growth, anticipated to increase by USD 2.9 billion from 2025 to 2029. With a compounded annual growth rate (CAGR) projected at approximately 5.3% during this forecast period, there are clear signals of expanding consumer demand for...

Continue Reading
Innovative Partnership Aims to Revolutionize Retinal Disease Treatment

Updated Category News Views 300

Innovative Collaboration to Tackle Retinal Diseases Boehringer Ingelheim and Palatin Technologies have taken a monumental step towards addressing retinal diseases by joining forces to create potential first-in-class treatments. This partnership is pivotal in strengthening Boehringer’s diverse pipeline in Eye Health, particularly for conditions such as diabetic...

Continue Reading
BioAtla Releases Promising Findings on BA3182 for Adenocarcinoma

Updated Category News Views 125

BioAtla Showcases BA3182 Advances at ESMO Gastrointestinal Congress BioAtla, Inc. (Nasdaq: BCAB), a pioneering biotechnology firm specializing in Conditionally Active Biologic (CAB) therapeutic antibodies, has shared exciting preliminary results from the ongoing dose escalation study of BA3182, a bispecific T-cell engager, at the European Society for Medical Oncology...

Continue Reading